Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
-
Feb 21, 2024 (filed on Feb 29, 2024)Insider Name:Vazquez ChrisOwnership Type:Direct OwnershipSecurities:Stock Options (Right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:14,280Price:--
-
Feb 21, 2024 (filed on Feb 29, 2024)Insider Name:Pestano Gary AnthonyOwnership Type:Direct OwnershipSecurities:Stock Options (Right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:3,690Price:--
-
Feb 21, 2024 (filed on Feb 29, 2024)Insider Name:O'Kane KieranOwnership Type:Direct OwnershipSecurities:Stock Options (Right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:35,307Price:--
-
Feb 21, 2024 (filed on Feb 29, 2024)Insider Name:Hutton ScottOwnership Type:Direct OwnershipSecurities:Stock Options (Right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:180,926Price:--
-
Feb 21, 2024 (filed on Feb 29, 2024)Insider Name:Cowie Robin HarperOwnership Type:Direct OwnershipSecurities:Stock Options (Right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:62,358Price:--
-
Feb 12, 2024 (filed on Feb 12, 2024)Insider Name:Vazquez ChrisOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-922Price:$1.66
-
Feb 12, 2024 (filed on Feb 12, 2024)Insider Name:Pestano Gary AnthonyOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-5,022Price:$1.66
-
Feb 12, 2024 (filed on Feb 12, 2024)Insider Name:O'Kane KieranOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-5,412Price:$1.66
-
Feb 12, 2024 (filed on Feb 12, 2024)Insider Name:Hutton ScottOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-29,708Price:$1.66
-
Feb 12, 2024 (filed on Feb 12, 2024)Insider Name:Cowie Robin HarperOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-8,699Price:$1.66
Filings by filing date
-
Feb 21, 2024 (filed on Feb 29, 2024)Insider Name:Vazquez ChrisOwnership Type:Direct OwnershipSecurities:Stock Options (Right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:14,280Price:--
-
Feb 21, 2024 (filed on Feb 29, 2024)Insider Name:Pestano Gary AnthonyOwnership Type:Direct OwnershipSecurities:Stock Options (Right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:3,690Price:--
-
Feb 21, 2024 (filed on Feb 29, 2024)Insider Name:O'Kane KieranOwnership Type:Direct OwnershipSecurities:Stock Options (Right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:35,307Price:--
-
Feb 21, 2024 (filed on Feb 29, 2024)Insider Name:Hutton ScottOwnership Type:Direct OwnershipSecurities:Stock Options (Right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:180,926Price:--
-
Feb 21, 2024 (filed on Feb 29, 2024)Insider Name:Cowie Robin HarperOwnership Type:Direct OwnershipSecurities:Stock Options (Right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:62,358Price:--
-
Feb 08, 2024 (filed on Feb 12, 2024)Insider Name:Vazquez ChrisOwnership Type:Direct OwnershipSecurities:Restricted Stock UnitsNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-4,694Price:--
-
Feb 08, 2024 (filed on Feb 12, 2024)Insider Name:Vazquez ChrisOwnership Type:Direct OwnershipSecurities:Restricted Stock UnitsNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-602Price:--
-
Feb 08, 2024 (filed on Feb 12, 2024)Insider Name:Vazquez ChrisOwnership Type:Direct OwnershipSecurities:Stock Options (Right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:34,966Price:--
-
Feb 08, 2024 (filed on Feb 12, 2024)Insider Name:Vazquez ChrisOwnership Type:Direct OwnershipSecurities:Restricted Stock UnitsNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:17,483Price:--
-
Feb 12, 2024 (filed on Feb 12, 2024)Insider Name:Vazquez ChrisOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-922Price:$1.66
News
Biz Brief
Sector: Healthcare | Industry: Healthcare Facilities & Services |
See Regulatory Filings on SEC |
Company Contact | |
Address: | Suite 100, 2970 Wilderness Place BOULDER CO 80301 |
Tel: | 1-212-9152568 |
Website: | https://www.biodesix.com |
IR: | See website |
Key People | ||
Scott Hutton President, Chief Executive Officer, Director | Robin Harper Cowie Chief Financial Officer, Treasurer, Secretary | Christopher Vazquez Chief Accounting Officer |
Business Overview |
Biodesix, Inc. (Biodesix) is a data-driven diagnostic solutions company. Biodesix is focused on using technologies with its artificial intelligence platform to discover, develop, and commercialize solutions for clinical unmet needs in lung disease. Biodesix is providing diagnostic testing services associated with blood-based lung tests; coronavirus disease tests and providing biopharmaceutical companies with services that include diagnostic research, clinical research, development, and testing services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics. Its blood-based lung cancer tests include Nodify XL2 and Nodify CDT tests, and GeneStrat and VeriStrat tests. Biodesix also offers SARS-CoV-2 tests under the Biodesix WorkSafe testing program, such as Bio-Rad SARS-CoV-2 ddPCR test, Platelia SARS-CoV-2 Total Ab test and cPass SARS-CoV-2 Neutralizing Antibody testing. |
Financial Overview |
For the fiscal year ended 31 December 2023, Biodesix Inc revenues increased 28% to $49.1M. Net loss decreased 20% to $52.1M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects (Loss) gain on debt extinguishments, net decrease from $7M (expense) to $0K, Research and development - Balancing v decrease of 24% to $9.7M (expense). |
Employees: | 217 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $147.62M as of Dec 31, 2023 |
Annual revenue (TTM): | $49.09M as of Dec 31, 2023 |
EBITDA (TTM): | -$37.97M as of Dec 31, 2023 |
Net annual income (TTM): | -$52.15M as of Dec 31, 2023 |
Free cash flow (TTM): | -$45.93M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | $8.99M as of Dec 31, 2023 |
Shares outstanding: | 96,942,061 as of Feb 23, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |